Proparacaine hydrochloride
PreclinicalSmall molecule
Proparacaine hydrochloride is one of 78 small molecule programs targeting Cataract. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Cataract
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Eylea
RegeneronApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Toradol
RocheApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Cipro
BayerApproved
Voltaren
NovartisApproved
Levaquin
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
AIN1 trial
Proparacaine and Mydriatic Eye Drops
Terminated·—·N/A·NCT01266824·5 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Proparacaine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University